LCT shares rise as company completes Parkinson’s trial

Shares of Australasian biotech company Living Cell Technologies rose 7.4 percent to 8.7 Australian cents on the ASX today after it announced the completion of the first stage of a clinical trial underway in Auckland of its planned treatment for Parkinson’s disease.

The shares have bounced around a range of 4-to-11 Australian cents this year as the company awaits next year’s outcome of the Phase 11b clinical trial of NTCELL, which would be the world’s first disease-modifying treatment for Parkinson’s.

Read more